Enspire DBS Therapy, Inc. has secured $10.3 million in new investment capital from investors. The company, in partnership with Cleveland Clinic, is focused on developing a proprietary deep brain stimulation (DBS) therapy designed to restore motor function for stroke survivors living with disability. This significant funding round will bolster Enspire's ongoing efforts, particularly as it sponsors RESTORE, a pivotal Phase II/III clinical trial evaluating its DBS therapy for stroke recovery.
The capital infusion highlights investor confidence in Enspire DBS Therapy's innovative approach to addressing a critical unmet medical need. This investment is crucial for advancing the company's clinical development roadmap. The funds are earmarked to support the continued progress of the RESTORE trial, ensuring the rigorous evaluation of the therapy's safety and efficacy. Furthermore, the funding will facilitate the refinement and scaling of their proprietary DBS technology.
Enspire DBS Therapy's mission is to provide a transformative treatment option for the millions of individuals worldwide who suffer from persistent motor deficits following a stroke. The successful completion of this funding round provides the necessary resources to accelerate the clinical validation process, moving the therapy closer to potential availability for patients. This investment underscores the potential impact of deep brain stimulation in neurological rehabilitation.
Looking ahead, Enspire DBS Therapy plans to strategically deploy this capital to achieve key milestones in its clinical development program. The company aims to expand its research capabilities and strengthen its operational infrastructure as it progresses through the later stages of clinical trials. This funding positions Enspire to continue its dedicated work towards bringing an innovative solution to stroke survivors and establishing a new standard of care in post-stroke recovery.
